Abstract
Systemic administration of anti-PCSK9 antibodies induces dramatic reductions in LDL-cholesterol levels, and the effect of this therapy on LDL-receptor activity seems to be additive to that of statin therapy. Inhibition of PCSK9 is potentially very important to the clinician, and should enable more patients to achieve their LDL-cholesterol-level goal.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Anticholesteremic Agents / administration & dosage
-
Anticholesteremic Agents / therapeutic use*
-
Cholesterol, LDL / metabolism
-
Clinical Trials as Topic
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Hypercholesterolemia / drug therapy*
-
Proprotein Convertase 9
-
Proprotein Convertases / antagonists & inhibitors*
-
Serine Endopeptidases
Substances
-
Antibodies, Monoclonal
-
Anticholesteremic Agents
-
Cholesterol, LDL
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
PCSK9 protein, human
-
Proprotein Convertase 9
-
Proprotein Convertases
-
Serine Endopeptidases